Saúde Pública/Medicina Humanitária
1/3 dos pacientes hospitalizados com COVID-19 apresentam alterações pulmonares depois de 1 ano.
7 Mai, 2021 | 10:51hComentários: One third of patients hospitalized with COVID-19 have lung changes after a year – University of Southampton E An integrated understanding of long-term sequelae after acute COVID-19 – The Lancet Respiratory Medicine
COVID-19 já causou 6,9 milhões de mortes ao redor do mundo, mais que o dobro demonstrado pelos relatórios oficiais.
7 Mai, 2021 | 10:50hComunicado de Imprensa: COVID-19 has caused 6.9 million deaths globally, more than double what official reports show – Institute for Health Metrics and Evaluation
Relatório: Estimation of total mortality due to COVID-19 – Institute for Health Metrics and Evaluation
Comentários: New analysis finds global Covid death toll is double official estimates – STAT E Global COVID-19 death toll more than double official estimates – IHME – Reuters
Estudo de coorte: Eventos arteriais, tromboembolismo venoso, trombocitopenia e sangramento após vacinação com Oxford-AstraZeneca ChAdOx1-S: 11 eventos tromboembólicos venosos em excesso por 100.000 vacinações; 2,5 tromboses venosas cerebrais em excesso por 100.000 vacinações.
7 Mai, 2021 | 10:48hEditorial: Thromboembolism and the Oxford-AstraZeneca vaccine – The BMJ
Comentários: Thrombosis and bleeding after the Oxford-AstraZeneca covid-19 vaccination – The BMJ Opinion E Putting risks into context: covid-19 vaccines and blood clots – The BMJ Opinion E Expert reaction to study from Denmark and Norway looking at rare blood clots after the Oxford-AstraZeneca vaccine – Science Media Centre
Comentário no Twitter
NEW research sheds more light on rate of rare blood clots after Oxford-AstraZeneca vaccine
Rate of adverse events low; benefits of the vaccine still outweigh risks in most situations, say researchershttps://t.co/LslgvzWlWi @Pottegard
— The BMJ (@bmj_latest) May 6, 2021
Opinião | Covid-19: vacina Sputnik decola, graças ao impulso da revista Lancet.
7 Mai, 2021 | 10:46hCovid-19: Sputnik vaccine rockets, thanks to Lancet boost – The BMJ
Comentário no Twitter
Journals risk being used in place of regulators when they publish studies of novel vaccines that have not yet been authorised by a major regulator @DoctorChrisVT unpicks the story of the Sputnik V vaccine https://t.co/lYf7l0lXcy
— The BMJ (@bmj_latest) May 6, 2021
Em ação surpreendente, EUA se posiciona a favor da liberação de patentes das vacinas contra COVID. “A administração Biden atrai aplausos dos pesquisadores em saúde pública e irrita a indústria farmacêutica.”
6 Mai, 2021 | 07:49hIn shock move, US backs waiving patents on COVID vaccines – Nature
Ver também: U.S. will back proposal to waive intellectual property rights and boost Covid-19 vaccine production – STAT E Statement from the Executive Director of UNAIDS, Winnie Byanyima on the decision by the United States of America to support the TRIPS waiver for COVID-19 vaccines – UNAIDS E WHO Director-General commends United States decision to support temporary waiver on intellectual property rights for COVID-19 vaccines – World Health Organization
Comentário no Twitter
These extraordinary times and circumstances of call for extraordinary measures.
The US supports the waiver of IP protections on COVID-19 vaccines to help end the pandemic and we’ll actively participate in @WTO negotiations to make that happen. pic.twitter.com/96ERlboZS8
— Ambassador Katherine Tai (@AmbassadorTai) May 5, 2021
Estudo randomizado: Vacina Novavax é 49,4% eficaz contra a variante B.1.351 do SARS-CoV-2.
6 Mai, 2021 | 07:46hEstudo observacional no Catar: Vacina da Pfizer–BioNTech se mostrou 89,5% eficaz contra a variante B.1.1.7 e 75% eficaz contra a variante B.1.351. A eficácia da vacina contra doença grave, crítica ou fatal com qualquer variante do SARS-CoV-2 foi de 97,4%.
6 Mai, 2021 | 07:45h
Comentário no Twitter
📍GET BOTH DOSES! Great variants & #COVID19 vaccine news—Pfizer/BioNTech vaccine had great efficacy of 89.5% vs #B117 🇬🇧 variant & 75% vs #B1351 🇿🇦 variant for infection—but only with 2 doses. The 1 dose efficacy was just ~29% vs #B117 & ~17% vs #B1351. 🧵https://t.co/SprUfggnmh pic.twitter.com/VDWHiLsQLL
— Eric Feigl-Ding (@DrEricDing) May 6, 2021
Estudo observacional em Israel: vacina da Pfizer-BioNTech é 95,3% eficaz contra a infecção por SARS-CoV-2.
6 Mai, 2021 | 07:43hComentários: Expert reaction to Israel nation-wide study looking at Pfizer vaccine effectiveness – Science Media Centre E Covid-19: Two doses of Pfizer vaccine are “highly effective” against infection, hospital admission, and death, study finds – The BMJ
Perspectiva | Quantas mortes por COVID são aceitáveis em um mundo pós-pandemia? “Mesmo depois das vacinações em massa, algumas internações e mortes por coronavírus serão inevitáveis – mas as opiniões divergem sobre quantas são consideradas demais para se retornar a uma relativa normalidade.”
6 Mai, 2021 | 07:38hHow many COVID deaths are acceptable in a post-pandemic world? – Nature
[Comunicado de Imprensa – ainda não publicado] Moderna anuncia dados iniciais positivos com dose de reforço contra as variantes preocupantes do SARS-CoV-2.
6 Mai, 2021 | 07:36hModerna Announces Positive Initial Booster Data Against SARS-CoV-2 Variants of Concern – Moderna
Comentário: We just got our first evidence that Moderna’s coronavirus booster shot works to fight variants – Insider
Comentário no Twitter
Moderna announces that a single dose of their #COVID19 booster shot provides a strong immunologic response to the variant first identified in South Africa (B.1.351) & Brazil (P.1).
This was also well tolerated.
Press release: https://t.co/q46Wx27BzI pic.twitter.com/16JpxrM4Vq
— Isaac Bogoch (@BogochIsaac) May 5, 2021
Great news
💥Single booster dose of 50 µg of mRNA-1273 or mRNA-1273.351 increased neutralizing titers against SARS-CoV-2 and two variants of concern (B.1.351, P.1)in previously vaccinated clinical trial participants💥 https://t.co/rzhDsgxEDh— Antibiotic Steward🆔🦠Bassam Ghanem (@ABsteward) May 6, 2021